( logy AG Cytos Biotechnology AG is a pu...)Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy,Health

logy AG
Cytos Biotechnology AG is a public Swiss biotechnology company that specializes in the discovery, development
and commercialization of a new class of biopharmaceutical products – the ImmunodrugsTM. ImmunodrugsTM are
intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people
worldwide. ImmunodrugsTM are designed to instruct the patient’s immune system to produce desired therapeutic
antibody or T cell responses that modulate chronic disease processes. Taking advantage of the high flexibility of its
ImmunodrugTM platform, Cytos Biotechnology has built a pipeline of different ImmunodrugTM candidates in various
disease areas, of which 6 are currently in clinical development. The ImmunodrugTM candidates are developed both
in-house and together with Novartis and Pfizer Animal Health. Founded in 1995 as a spin-off from the Swiss
Federal Institute of Technology (ETH) in Zurich, the company is located in Schlieren (Zurich). Currently, the
company has 130 employees. Cytos Biotechnology AG has been listed on the SWX Swiss Exchange (SWX:CYTN) since
October 2002.

Glossary
Allergen tolerance: non-reactivity to a certain allergen or reactivity only up to the level of a predefined minimal symptom score.
Allergic rhinitis: a condition due to allergy that mimics a cold. Rhinitis means "inflammation of the nasal mucous membranes".
Atopic dermatitis: a chronic skin disease; a certain type of eczema. Is accompanied by an inherited tendency to develop allergic diseases.
Conjunctival provocation test: a commonly used allergy test to monitor the allergic disease status of an individual.
Disease-modifying: in contrast to symptomatic treatment, a disease-modifying treatment aims at addressing the cause of disease and to
modify disease progression.

DNA: deoxyribonucleic acid; genetic information of
'"/>




Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis